Another example is a humanized afucosylated anti-CCR4 antibody, mogamulizumab (trade name Poteligeo), which was approved by the FDA for cutaneous T cell lymphoma (CTCL) in August 2018 [66]. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.